Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD, Najla Al Ali, M.Sc, Onyee Chan, MD, Eric Padron, MD, David A. Sallman, MD, Rami S. Komrokji, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-138833

Published: 2020

Journal Articles

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

Seongseok Yun, MDPhD, Onyee Chan, MD, Daniel Kerr, MDPhD, Nicole D. Vincelette, PhD, Afshan Idrees, MD MPH, Qianxing Mo, PhD, Kendra Sweet, MD, Jeffrey E. Lancet, MD, Mohamed A kharfan-Dabaja, MDMBA, Ling Zhang, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133391

Published: 2020

Journal Articles

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Onyee Chan, MD, Najla Al Ali, MD, David A. Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141960

Published: 2020

Journal Articles

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Anthony Hunter, MD, Chetasi Talati, MD, David A Sallman, MD, Hannah Asghari, MD BS, Jinming Song, MD PhD, Mohammad Hussaini, MD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Andrew T Kuykendall, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Asmita Mishra, MD

Blood (2019) 134 (Supplement_1): 149.

https://doi.org/10.1182/blood-2019-131530

Published: 2019

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Chetasi Talati, MD, Hannah H Asghari, MD, Jinming Song, MD PhD, Mohammad Hussaini, MD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 2052.

https://doi.org/10.1182/blood-2019-129742

Published: 2019

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Yumeng Zhang, MD, Hannah H Asghari, MD, Onyee Chan, MD, Dasom Lee, MD, Martine Extermann, MD, Najla Al Ali, M.Sc, Yehuda E. Deutsch, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, David A Sallman, MD, Chetasi Talati, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 1368.

https://doi.org/10.1182/blood-2019-127772

Published: 2019

Journal Articles

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

David M Swoboda, MD, Jung-Hoon Lee, MD, Onyee Chan, MD, Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Eric Padron, MD, Alan F. List, MD, Mohammad O Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD

Blood (2019) 134 (Supplement_1): 4244.

https://doi.org/10.1182/blood-2019-124772

Published: 2019

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Hannah Asghari, MD BS, Chetasi Talati, MD, Alexandra Achille, John J. Powers, BS, Eva Sahakian, PhD, Onyee Chan, MD, Dawne N Shelton, PhD, Leidy Isenalumhe, MD, Lisa Nodzon, PhD ARNP, AOCNP, Kendra L. Sweet, MD, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 3382.

https://doi.org/10.1182/blood-2019-131207

Published: 2019

Journal Articles

Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience

Onyee Chan, MD, Chetasi Talati, MD, Leidy Isenalumhe, MD, Michael Fradley, MD, Samantha Shams, MD, Javier Pinilla Ibarz, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2018-99-115660

Published: 2018

Journal Articles

Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy

Chetasi Talati, MD, Aaron D Goldberg, MDPhD, Amanda Przespolewski, DO, Onyee Chan, MD, Najla Al Ali, M.Sc, Christopher Famulare, MS, David A Sallman, MD, Eric Padron, MD, Andrew Kuykendall, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Eunice S. Wang, MD, Martin S. Tallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 665.

https://doi.org/10.1182/blood-2018-99-119879

Published: 2018

Journal Articles

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Chetasi Talati, MD, Aaron D Goldberg, MD PhD, Pinkal Desai, MD MPH, Onyee Chan, MD, Christopher Famulare, MS, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Hugo F. Fernandez, MD, Yehuda E. Deutsch, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Martin S. Tallman, MD, David A Sallman, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2018-99-117412

Published: 2018

Journal Articles

Outcome of Immune-Suppressive Therapy (IST) and Hematopoietic Stem Cell Transplantation (SCT) in Patients with Aplastic Anemia: A Retrospective Single Center Experience

Onyee Chan, MD, Onyemaechi Okolo, MD, Muhammad Husnain, MD, Irbaz Bin Riaz, MD, Faiz Anwer, MD

Blood (2016) 128 (22): 5081.

https://doi.org/10.1182/blood.V128.22.5081.5081

Published: 2016

NARROW

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience

Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Outcome of Immune-Suppressive Therapy (IST) and Hematopoietic Stem Cell Transplantation (SCT) in Patients with Aplastic Anemia: A Retrospective Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only